Titre : Hepatitis C Drug’s Lower Cost Paves Way For Medicaid, Prisons To Expand Treatment
link : Hepatitis C Drug’s Lower Cost Paves Way For Medicaid, Prisons To Expand Treatment
Hepatitis C Drug’s Lower Cost Paves Way For Medicaid, Prisons To Expand Treatment
Hepatitis C Drug’s Lower Cost Paves Way For Medicaid, Prisons To Expand TreatmentBy Michelle Andrews
The Delaware resident was diagnosed with hepatitis C more than two years ago, but she doesn’t qualify yet for the Medicaid program’s criteria for treatment with a new class of highly effective but pricey drugs. The recent approval of a less expensive drug that generally cures hepatitis C in just eight weeks may make it easier for more insurers and correctional facilities to expand treatment.
In addition, Mavyret’s price tag of $26,400 for a course of treatment is significantly below that of other hepatitis C drugs whose sticker price ranges from about $55,000 to $95,000 to beat the disease. Patients and insurers often pay less, however, through negotiated insurance discounts and rebates.
Read More: http://ift.tt/2yWaXtc
Related:
The controversy over expensive new drugs for hepatitis C
Link to research and news articles addressing the high cost of hepatitis C drugs; insurance restrictions - private insurers/Medicaid - and availability of generic versions/India, Egypt and other lower-income countries or through online "buyers clubs"
Thus articles Hepatitis C Drug’s Lower Cost Paves Way For Medicaid, Prisons To Expand Treatment
that is all articles Hepatitis C Drug’s Lower Cost Paves Way For Medicaid, Prisons To Expand Treatment This time, hopefully can provide benefits to you all. Okay, see you in another article post.
You are now reading the article Hepatitis C Drug’s Lower Cost Paves Way For Medicaid, Prisons To Expand Treatment the link address https://newsaninpiration.blogspot.com/2017/10/hepatitis-c-drugs-lower-cost-paves-way.html
0 Response to "Hepatitis C Drug’s Lower Cost Paves Way For Medicaid, Prisons To Expand Treatment"
Post a Comment